Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4088708
Max Phase: Preclinical
Molecular Formula: C157H233N41O46
Molecular Weight: 3430.83
Molecule Type: Small molecule
Associated Items:
ID: ALA4088708
Max Phase: Preclinical
Molecular Formula: C157H233N41O46
Molecular Weight: 3430.83
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(N)=O)C(C)C
Standard InChI: InChI=1S/C157H233N41O46/c1-17-81(10)127(154(242)176-85(14)133(221)184-112(65-92-68-167-98-36-25-24-35-96(92)98)145(233)186-107(60-78(4)5)146(234)195-125(79(6)7)152(240)183-100(37-26-28-56-158)136(224)169-71-118(207)177-99(39-30-58-166-157(163)164)135(223)168-70-117(162)206)197-147(235)110(61-88-31-20-18-21-32-88)187-141(229)105(51-55-123(214)215)182-140(228)101(38-27-29-57-159)179-131(219)83(12)173-130(218)82(11)175-139(227)104(48-52-116(161)205)178-119(208)72-170-138(226)103(50-54-122(212)213)181-142(230)106(59-77(2)3)185-143(231)108(63-90-40-44-94(203)45-41-90)188-150(238)114(74-199)192-144(232)109(64-91-42-46-95(204)47-43-91)190-153(241)126(80(8)9)196-149(237)113(67-124(216)217)189-151(239)115(75-200)193-156(244)129(87(16)202)198-148(236)111(62-89-33-22-19-23-34-89)191-155(243)128(86(15)201)194-120(209)73-171-137(225)102(49-53-121(210)211)180-132(220)84(13)174-134(222)97(160)66-93-69-165-76-172-93/h18-25,31-36,40-47,68-69,76-87,97,99-115,125-129,167,199-204H,17,26-30,37-39,48-67,70-75,158-160H2,1-16H3,(H2,161,205)(H2,162,206)(H,165,172)(H,168,223)(H,169,224)(H,170,226)(H,171,225)(H,173,218)(H,174,222)(H,175,227)(H,176,242)(H,177,207)(H,178,208)(H,179,219)(H,180,220)(H,181,230)(H,182,228)(H,183,240)(H,184,221)(H,185,231)(H,186,233)(H,187,229)(H,188,238)(H,189,239)(H,190,241)(H,191,243)(H,192,232)(H,193,244)(H,194,209)(H,195,234)(H,196,237)(H,197,235)(H,198,236)(H,210,211)(H,212,213)(H,214,215)(H,216,217)(H4,163,164,166)/t81-,82-,83-,84-,85-,86+,87+,97-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,125-,126-,127-,128-,129-/m0/s1
Standard InChI Key: RUVNEHWZXWUSQL-VHLMGYJESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3430.83 | Molecular Weight (Monoisotopic): 3428.7153 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Plisson F, Hill TA, Mitchell JM, Hoang HN, de Araujo AD, Xu W, Cotterell A, Edmonds DJ, Stanton RV, Derksen DR, Loria PM, Griffith DA, Price DA, Liras S, Fairlie DP.. (2017) Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling., 127 [PMID:27823886] [10.1016/j.ejmech.2016.10.044] |
Source(1):